Proton pump inhibitor prescribing patterns in the UK: a primary care database study

被引:92
作者
Othman, Fatmah [1 ]
Card, Timothy R. [1 ]
Crooks, Colin J. [1 ]
机构
[1] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham, England
关键词
proton pump inhibitor; database; prevalence; pattern; general practice; pharmacoepidemiology; GASTROESOPHAGEAL-REFLUX DISEASE; GENERAL-PRACTICE; CLINICAL-PRACTICE; STEP-DOWN; THERAPY; DISCONTINUATION; POPULATION; MANAGEMENT; VALIDITY; ARTICLE;
D O I
10.1002/pds.4043
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeTo determine the prevalence and pattern of proton pump inhibitor (PPI) prescription and the practices employed to reduce PPI use in the UK general population. MethodsThe UK's Clinical Practice Research Database was used to identify individuals who were issued with 1 PPI prescription during the period 1990-2014. Point and period prevalence of PPI use were estimated annually. Additionally, new users of PPI therapy who had 5years of follow-up data were included in a cohort analysis to describe patterns of cessation and duration of PPI use. ResultsBoth the period and point prevalence of PPI use increased between 1990 and 2014 (period prevalence increased from 0.2 to 15.0% and point from 0.03 to 7.7%). A total of 596334 new users of PPI therapy in the cohort study received 8784272 prescriptions. Of these, 26.7% used PPI therapy long term (1year continuously), while 3.9% remained on PPI therapy for 5years. Clear attempts to step down dose were identified in 39.9% of long-term users, while this was 47% in patients whose initial indication did not mandate long-term use. ConclusionA considerable increase in PPI use was observed in UK general practice. Of long-term PPI users, 60% did not have an attempt to discontinue or step down. Considerable opportunities may therefore exist to reduce the cost and side effects of PPI use through improving adherence to recommended withdrawal strategies. Copyright (c) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1079 / 1087
页数:9
相关论文
共 41 条
  • [1] Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care
    Ahrens, D.
    Behrens, G.
    Himmel, W.
    Kochen, M. M.
    Chenot, J. -F.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (08) : 767 - 773
  • [2] [Anonymous], 2014, 1 3 5 PROT PUMP INH
  • [3] Bashford JNR, 1998, BRIT MED J, V317, P452
  • [4] Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection
    Bavishi, C.
    DuPont, H. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1269 - 1281
  • [5] Discontinuation of proton pump inhibitors in patients on long-term therapy:: a double-blind, placebo-controlled trial
    Bjornsson, E.
    Abrahamsson, H.
    Simren, M.
    Mattsson, N.
    Jensen, C.
    Agerforz, P.
    Kilander, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (06) : 945 - 954
  • [6] Proton pump inhibitors: potential cost reductions by applying prescribing guidelines
    Cahir, Caitriona
    Fahey, Tom
    Tilson, Lesley
    Teljeur, Conor
    Bennett, Kathleen
    [J]. BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [7] Recent Safety Concerns With Proton Pump Inhibitors
    Chen, Joan
    Yuan, Yuhong Cathy
    Leontiadis, Grigorios I.
    Howden, Colin W.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (02) : 93 - 114
  • [8] CPRD, 2015, CLIN PRACT RES DAT
  • [9] Repeat prescribing - Scale, problems and quality management in ambulatory care patients
    De Smet, PAGM
    Dautzenberg, M
    [J]. DRUGS, 2004, 64 (16) : 1779 - 1800
  • [10] Department of Health, 2000, PRESCR COST AN ENGL